Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapy

3 Oct 2024

Abstract excerpt

Objective To investigate the relationship between the gut microbiome and the response to anti-PD-1-based combination therapy in unresectable hepatocellular carcinoma (HCC). We aimed to identify potential non-invasive biomarkers and new strategies to modulate immunotherapy in HCC. Methods In this study, fresh stool samples and clinical data were collected from unresectable HCC patients treated with anti-PD-1-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Gut microbiota and health
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39421302
DOI: 10.3389/fgene.2024.1366131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapyPMID 39421302Read ↗

Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti‐PD ‐1 based immunotherapy in hepatocellular carcinomaSemantic proximity Read ↗

The gut microbiota modulates responses to anti–PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumorsSemantic proximity Read ↗

Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinomaSemantic proximity Read ↗

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic targetSemantic proximity Read ↗

Specific gut microbiome signature predicts hepatitis B virus-related hepatocellular carcinoma patients with microvascular invasionSemantic proximity Read ↗

Identification of a brand intratumor microbiome signature for predicting prognosis of hepatocellular carcinomaSemantic proximity Read ↗

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer PatientsSemantic proximity Read ↗

Predictable modulation of cancer treatment outcomes by the gut microbiota.Semantic proximity Read ↗

Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular CarcinomaSemantic proximity Read ↗

Specific gut microbiome signature predicts hepatitis B virus-related hepatocellular carcinoma patients with microvascular invasionSemantic proximity Read ↗

The Liver Microbiome Is Implicated in Cancer Prognosis and Modulated by Alcohol and Hepatitis BSemantic proximity Read ↗

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.